Armata Pharmaceuticals, Inc. (ARMP): Submission of Matters to a Vote of Security Holders
Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000921114 0000921114 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report
How this was made
The 30-second read
Why it matters
The board was elected for one-year terms; shareholders approved executive compensation on a non-binding basis and selected an annual frequency for future advisory votes; Ernst & Young LLP was ratified as independent auditor for FY ending Dec. 31, 2026.
Market read
This is a routine proxy/annual meeting outcome disclosure with no new operating or financial catalyst.
What to watch
Broker non-vote counts and the non-binding nature of compensation votes can matter for proxy optics, but the filing does not indicate contested outcomes that would imply a strategic shift.
Background
Form 8-K Item 5.07 reports the results of matters submitted to a vote of security holders following an annual meeting.
Ticker impact
Armata Pharmaceuticals filed an 8-K reporting shareholder votes on board directors, executive compensation, and auditor ratification at its June 11, 2026 meeting.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around governance/proxy matters.
The filing discloses voting results (director election, non-binding compensation approval/frequency, and E&Y ratification) without new financial guidance, transactions, or regulatory/clinical catalysts.
Market effects
Minimal; governance vote outcomes do not typically reset sector expectations for biotech/pharma.
Minimal; US-listed small/mid-cap corporate filing with no broader regional signal.
Minimal; no international transaction or regulatory action described.
Counterpoint
If the market had been pricing governance uncertainty, the finalized vote could reduce overhang, but the article provides no evidence of such uncertainty.
Key entities
- issuerArmata Pharmaceuticals, Inc.
US-listed company reporting shareholder vote results on board election, executive compensation advisory votes, and auditor ratification.
- auditorErnst & Young LLP
Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.
